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Introduction
In vivo electroporation or electrotransfer, the application of 
controlled electric pulses, enhances delivery of plasmid DNA 
(pDNA) to a wide variety of healthy tissues as well as many 
tumor types.1–4 Electrotransfer of pDNA encoding therapeutic 
genes substantially increases gene expression, enhancing 
subsequent therapeutic effects. This gene delivery technique 
has reached clinical trials for cancer therapies, cancer vac-
cines, and infectious disease vaccines.5
In studies of cancer therapies in preclinical models, several 
groups have observed inhibition of tumor growth, increased 
survival time, and complete tumor regression after intratu-
mor electrotransfer of oligonucleotides, plasmids devoid of 
encoded therapeutic genes, or plasmids encoding reporter 
genes. Antitumor effects have been described in melano-
mas,6–12 lung carcinomas,13,14 fibrosarcomas,15 pancreatic car-
cinomas,16 mammary tumors,17 and colorectal carcinomas.18–21 
After electrotransfer of pDNA devoid of a therapeutic gene, 
increased expression of several proinflammatory cytokine and 
chemokine proteins, particularly CCL3, CCL4, IL-1β, and IL-6, 
was observed in B16.F10 melanoma tumors and preceded 
tumor regression.10 Subsequent tumor-localized inflammation 
might contribute to the observed tumor regression.7,11
During the process of electrotransfer, pDNA theoreti-
cally enters the cell via endocytosis.22,23 This theory was 
supported in vivo by the observation that the inhibition 
of endocytosis also inhibits gene expression in skeletal 
muscle.24 The observations that DNA enters cell via endo-
cytosis during electrotransfer and that proinflammatory 
molecule expression was upregulated implicated the acti-
vation of the endosomal CpG motif DNA binding recep-
tor toll-like receptor 9 (TLR9).25 However, regression was 
induced by electrotransfer of calf thymus DNA or non-CpG 
containing control oligonucleotides,11 which are not classic 
TLR9 ligands.
Electrotransfer also delivers pDNA to the cytosol, which 
is probably a dead-end pathway with respect to transgene 
expression.26,27 The presence and activity of several DNA-
specific cytosolic pattern recognition receptors, also known 
as DNA sensors, has been demonstrated in a variety of cell 
types, including fibroblasts, tumor cells, and immune cells.28–31 
pDNA electrotransfer may enhance the availability of pDNA 
to cytosolic DNA sensor binding, inducing the production 
of proinflammatory cytokine and chemokines, particularly 
type I interferons.28,29,31 Therefore, all cell types residing in 
the tumor could potentially respond to pDNA electrotransfer. 
However, the tumor cells themselves are universally present. 
The purpose of this study was to investigate whether B16.
F10 mouse melanoma tumors and cells express cytosolic 
DNA sensors and whether these sensors respond to pDNA 
electrotransfer.
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In several preclinical tumor models, antitumor effects occur after intratumoral electroporation, also known as electrotransfer, 
of plasmid DNA devoid of a therapeutic gene. In mouse melanomas, these effects are preceded by significant elevation of 
several proinflammatory cytokines. These observations implicate the binding and activation of intracellular DNA-specific 
pattern recognition receptors or DNA sensors in response to DNA electrotransfer. In tumors, IFNβ mRNA and protein levels 
significantly increased. The mRNAs of several DNA sensors were detected, and DAI, DDX60, and p204 tended to be upregulated. 
These effects were accompanied with reduced tumor growth and increased tumor necrosis. In B16.F10 cells in culture, IFNβ 
mRNA and protein levels were significantly upregulated. The mRNAs for several DNA sensors were present in these cells; DNA-
dependent activator of interferon regulatory factor (DAI), DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (DDX60), and p204 were 
significantly upregulated while DDX60 protein levels were coordinately upregulated. Upregulation of DNA sensors in tumors 
could be masked by the lower transfection efficiency compared to in vitro or to dilution by other tumor cell types. Mirroring 
the observation of tumor necrosis, cells underwent a significant DNA concentration-dependent decrease in proliferation and 
survival. Taken together, these results indicate that DNA electrotransfer may cause the upregulation of several intracellular 
DNA sensors in B16.F10 cells, inducing effects in vitro and potentially in vivo.
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Tumor growth delay and complete tumor regression 
induced by pDNA electrotransfer of empty vector plasmid 
is preceded by increased expression of interferon-β
A single intratumor pDNA delivery by electrotransfer produced 
a significant growth delay in treated tumors (Figure 1a). In this 
experimental group, doubling time was decreased 3.2-fold; 
tripling time was decreased 2.8-fold. In addition, pDNA elec-
trotransfer induced complete tumor regression in 1 out of 
10 mice (Figure 1a). Hematoxylin & eosin (H&E) staining of 
tumor sections 6, 20, and 36 hours after pDNA electrotrans-
fer demonstrated a statistically significant increased proportion 
of necrosis after pDNA electrotransfer at all three time points 
compared to pDNA injection alone, electrotransfer alone, and in 
unmanipulated control tumors. The control tumors had approxi-
mately 4–6% necrosis, while the proportion of necrosis in the 
experimental groups increased with time (Figure 1b,e) and 
reached 84% 20 hours after pDNA electrotransfer. The pres-
ence of inflammatory immune cells was observed at the tumor 
borders in the pDNA electrotransfer group (Supplementary 
Figure S1). Due to the early onset of necrotic cell death, the 
proportion of apoptotic cells as indicated by cleaved caspase 
3 was evaluated at 6 hours after pDNA electrotransfer. No sta-
tistically significant difference in proportion of apoptotic cells 
between the groups was observed. At 6 hours post-treatment, 
necrosis was evenly distributed throughout the tumor tissue 
and no clear sharp boundary was observed between necrotic 
and apoptotic areas and viable tissue (Figure 1e). These 
results indicate that necrosis is more likely to occur after pDNA 
electrotransfer than apoptosis.
Interferon-β (IFNβ) is a marker of cytosolic DNA sensor acti-
vation.32–40 The effect of pDNA electrotransfer on intratumoral 
IFNβ mRNA and protein levels in tumors was determined. 
Real-time reverse transcriptase polymerase chain reaction 
(RT-PCR) demonstrated that while no change in IFNβ mRNA 
levels was detected in control tumors, tumors injected with 
pDNA, or tumors subjected to electrotransfer alone, the com-
bination of pDNA and electrotransfer produced an increase 
of approximately 13-fold (P < 0.05)  (Figure 1c). IFNβ  protein 
levels correlated with the mRNA levels  (Figure 1d); an 11-fold 
increase was observed only in the tumors subjected to the 
combination of pDNA injection and electrotransfer (P < 0.01).
Tumor mRNA levels for several DNA sensors were deter-
mined by real-time RT-PCR 4 hours after the procedure 
(Table 1). While the all mRNAs tested except RIG-1 (retinoic 
acid inducible gene upregulation of type I interferon) and 
p202 were detected in the tumors, none were significantly 
upregulated in any experimental group. Either pDNA injection 
or pDNA electrotransfer tended to increase DDX60 (DEAD 
(Asp-Glu-Ala-Asp) box polypeptide 60) levels, while pDNA 
electrotransfer alone tended to increase DAI (DNA-depen-
dent activator of interferon regulator factors) and p204 mRNA 
levels. Notably, the mRNA levels for the endosomal DNA sen-
sor TLR9 did not change.
pDNA electrotransfer directly effects B16.F10 melanoma 
cells
In vitro experiments were performed to determine if IFNβ was 
produced by B16.F10 cells subjected to pDNA electrotrans-
fer. An increase in IFNβ mRNA of nearly 60-fold (P < 0.01) 
was detected in cells subjected to pDNA electrotransfer when 
compared to pDNA exposure alone, electrotransfer alone, 
and unmanipulated control cells (Figure 2a). This observa-
tion was supported by a fivefold increase in IFNβ promoter 
activation as measured by a reporter assay (Figure 2b, 
P < 0.05), indicating that transcriptional upregulation may be 
partially responsible. A significant increase in IFNβ  protein 
levels was detected in B16.F10 cells by enzyme-linked immu-
nosorbent assay (ELISA) (Figure 2c, P < 0.01). Flow cytom-
etry demonstrated that the number of cells expressing IFNβ 
protein increased nearly sixfold  (Figure 2d, P < 0.01) with 
an increase in median fluorescent intensity of nearly 10-fold 
(Figure 2e, P < 0.01) after pDNA electrotransfer.
DNA sensor mRNA levels in B16.F10 cells were determined 
(Table 2). The mRNAs for TLR9 and AIM2 (absent in mela-
noma 2) were not detected. TLR9 is expressed in immune 
cells, while AIM2 is not normally expressed in melanoma 
cells. As with B16.F10 tumors, RIG-1 and p202 mRNAs were 
not detected. Interestingly, mRNAs for cGAS (cyclic guano-
sine monophosphate-adenosine monophosphate synthase), 
DDX41 (DEAD (Asp-Glu-Ala-Asp) box polypeptide 41), and 
LRRFIP1 (leucine-rich repeat flightless-interacting protein 1) 
as well as the CpG motif-specific sensors DHX9 (DexD/H-
box helicase family 9) and DHX36 (DexD/H-box helicase 
family 36) were detected, although they were not upregulated 
in any group. The mRNAs of three cytosolic DNA sensors 
significantly increased after pDNA electrotransfer in B16.
F10 cells. DAI mRNA was upregulated by approximately 355-
fold, DDX60 mRNA was upregulated by more than 6-fold, 
and p204 mRNA was upregulated by approximately 18-fold. 
Upregulation of cytosolic DNA sensors after pDNA electro-
transfer was confirmed using a different electroporation pro-
tocol (EP1). After EP1, similar mRNAs were upregulated as 
shown in Table 2. Although these pulse protocols demon-
strated similar transfection efficiencies  (Figure 3b), different 
levels of upregulation of DAI (P < 0.001) and p204 (P < 0.01) 
mRNAs were detected. Therefore, transfection efficiency 
may not relate to DNA sensor upregulation. Furthermore, 
the upregulation of cytosolic DNA sensors was confirmed 
also with an alternate plasmid, pEGFP-N1, which encodes 
enhanced GFP (pEGFP-N1) in another backbone. Electro-
transfer of pEGFP-N1 resulted in DDX60 mRNA upregulation 
by 3.98 ± 1.15, DAI mRNA by 7.88 ± 0.15, and p204 mRNA by 
4.46 ± 3.18-fold.
An increase in DDX60 protein detected by two methods 
confirmed the mRNA results. A sevenfold increase in cells 
expressing DDX60 (Figure 2f, P < 0.05) and a 10-fold 
increase in the median fluorescent intensity in these cells 
was detected by flow cytometric after pDNA electrotransfer 
(Figure 2g, P < 0.05). On western blots, the DDX60 protein 
was detected in cell lysate only after pDNA electrotransfer 
as predicted by the 198 kDa band. No DDX60 protein was 
detected in any other experimental group (Figure 2h).
We next determined if pDNA electrotransfer using different 
protocols had a direct effect on melanoma cell survival. The 
exposure of cells to pDNA had no effect on cell survival, while 
the application of electric pulses alone decreased viability by 
80% after EP and 30% after EP1 72 hours post-treatment. 
A significant pDNA concentration-dependent decrease in cell 
survival was observed after pDNA electrotransfer using both 
www.moleculartherapy.org/mtna
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protocols (Figure 3a, P < 0.01); however, the decrease of 
survival after EP1 was smaller than after EP. The transfection 
efficiency with these electroporation protocols was identical 
(Figure 3b).
The mechanisms of cell death were investigated in vitro to 
confirm our previous findings in vivo. Using a flow cytometric 
assay, relative changes in annexin V and 7AAD detection are 
characteristic of apoptotic or necrotic cell death. Electrotrans-
fer of pDNA with EP pulses caused necrotic cell death as indi-
cated by a higher percentage of annexin V and 7AAD-positive 
cells (Supplementary Figure S2), while apoptosis after pDNA 
electrotransfer with these pulses was not increased as indi-
cated by no change in percentage of cells positive for annexin 
V (Supplementary Figure S2). In contrast, electrotransfer 
of pDNA with EP1 pulses caused predominantly apoptosis, 
while necrosis was also increased (Figure 3c). These findings 
indicate that not only plasmid DNA but also pulse parameters 
are responsible for triggering cell death mechanisms. More-
over, morphological changes confirmed the flow cytometry 
data; necrosis as well as apoptosis were clearly seen after 
pDNA electrotransfer (Figure 3d).
Theoretically, the inhibition of endocytosis could modu-
late DNA sensor upregulation. As expected, exposure to 
the general inhibitor of endocytosis MβCD reduced trans-
gene expression from approximately 30% of cells to 3% with 
reduced fluorescent intensity. MβCD pretreatment increased 
the levels of DDX60 and IFNβ mRNAs approximately twofold 
after pDNA electrotransfer (P < 0.05, P < 0.01 respectively), 
whereas DAI mRNA levels strongly decreased (Tables 2 and 3) 
(P < 0.05). TLR9 mRNA remained undetectable.
Figure 1  Effect of pDNA electrotransfer on tumor growth, necrosis, and expression of IFNβ. Commercially prepared vector plasmid 
(gWiz Blank) was electrotransferred into palpable B16.F10 melanoma tumors in the flanks of C57Bl/6 mice. Control, no tumor manipulation; 
EP, 50 μl saline injection followed by the delivery of eight 5 ms pulses with a voltage-to-distance ratio of 800 V/cm with a caliper electrode; 
pDNA, injection of 50 μl 2 mg/ml gWiz Blank plasmid; EP+pDNA, injection of 50 μl 2 mg/ml gWiz Blank plasmid followed by the delivery of eight 
5 ms pulses with a voltage-to-distance ratio of 800 V/cm with a caliper electrode. (a) Tumor growth was monitored as described. A complete 
response (CR, EP+pDNA CR) was observed in 1 out of 10 mice. Results represent two independent experiments, n = 5 for each experimental 
group in each experiment, and are expressed as mean ± SEM. (b) Necrosis was significantly increased in EP+pDNA group at all three time 
points compared to all other experimental groups. *P < 0.05 statistically significantly increased necrosis. (c) IFNβ mRNA levels as measured 
by real-time RT-PCR, n = 7–8. (d) IFNβ protein levels as measured by ELISA, n = 5–7. (e) Comparison of cleaved caspase-3 and hematoxylin 
& eosin staining of representative tumors sections 6 hours after pDNA electrotransfer. Results indicating that necrosis is more likely to occur 

















































































































The results of our study demonstrate that B16.F10 melanoma 
tumors secrete IFNβ after electrotransfer of pDNA (plasmid 
devoid of therapeutic genes) and that necrosis is produced. 
B16.F10 cells in culture express cytosolic DNA sensors and 
the expression of DAI, DDX60 and p204 mRNAs, DDX60 
protein, and IFNβ m RNA and protein are increased after 
pDNA electrotransfer. These changes in mRNA and protein 
levels are accompanied by DNA concentration-dependent 
cell death. These effects may be due to the activation of sig-
naling pathways mediated by the upregulated cytosolic DNA 
sensors.
In this study, a reproducible negative effect on tumor growth 
was observed using vector pDNA electrotransfer, confirm-
ing previous studies with other pulse protocols.6–21 However, 
while some tumor regression was observed, in this case the 
effect manifested itself primarily as a tumor growth delay 
(Figure 1), which is consistent with the histological observa-
tion that 16% of the tumor cells in vivo and 20% in vitro may 
retain viability. Although the identical plasmid (gWiz Blank) 
produced a higher level of complete regressions in a previous 
study,11 the decreased antitumor effect observed in this study 
may be due to the differences between the electroporation 
protocols employed.
Some unknown characteristic of the DNA composition is 
an important variable in this antitumor effect. Using a simi-
lar pulse protocol (ten 5 ms pulses at a voltage-to-distance 
ratio of 800 V/cm), three deliveries of pUC18 in 1 week pro-
duced complete, long-term regression in 70% of mice,7 while 
three deliveries of gWiz Blank produced complete, long-term 
regression in only 25% of mice.11 Delivery of calf thymus DNA 
with the same pulse protocol induces regression in 15% of 
tumors.11 Clearly, the composition of the DNA itself is an 
important variable.
This antitumor effect was independent of caspase-3 
and tumor necrosis was observed in the treated tumors 
 (Figure 1b,c). A direct cytotoxic effect against melanoma 
cells subjected to pDNA electrotransfer in culture was also 
demonstrated (Figure 3a). Here, the mechanism of cell death 
was predominantly necrosis as observed in tumors in vivo. 
Interestingly, the apoptotic cell death of melanoma cells in 
culture was increased after EP1, which was also described 
previously in tumors in vivo.41 The level of cell death did not 
correlate with the transfection efficiency. Although these two 
electroporation protocols produced similar levels of transgene 
expression (Figure 3b), subsequent cell death varied greatly 
(Figure 3a). Therefore, it seems that besides the composition 
of the DNA itself, the electrical parameters contribute to the 
mechanism of cell death following the pDNA electrotransfer.
After pDNA electrotransfer, increased mRNA levels of sev-
eral cytosolic DNA sensors associated with cell death were 
observed. For example, DAI is essential for programmed 
necrosis after murine cytomegalovirus infection.42 IFI16, the 
human ortholog of p204, is associated with p53-mediated 
apoptosis43 and caspase-1-dependent pyroptosis after CD4 
cells are exposed to HIV-1 transcripts.44 Activation of DNA 
sensors associated with electrotransfer may cause cell death.
In this study, we found that the mRNA of the proinflamma-
tory molecule IFNβ was significantly upregulated in B16.F10 
tumors subjected to pDNA electrotransfer (Figure 1c). Many 
putative intracellular DNA sensors inducing IFNβ expression 
have been described, and one of these, an unknown sen-
sor, or an unrelated mechanism might be responsible for 
the observed inflammatory protein production.28–31 While the 
mRNAs of several cytosolic sensors and the endosomal sen-
sor TLR9 remained unchanged, the mRNAs of the cytosolic 
DNA sensors DDX60, p204, and DAI tended to be upregu-
lated in tumors after pDNA electrotransfer (Table 2). The low 
transfection efficiency may have masked more pronounced 
Table 1 Fold changes in mRNA levels of DNA sensors in B16.F10 tumors four hours after pDNA electrotransfer
Sensora Control N EP N pDNA N EP+pDNA N
AIM2 1.08 ± 0.26 3 0.46 ± 0.12 3 1.24 ± 0.61 5 1.34 ± 0.28 5
cGAS 1.09 ± 0.33 3 0.56 ± 0.09 3 0.95 ± 0.20 5 2.09 ± 0.47 5
DAI 1.26 ± 0.50 3 0.58 ± 0.43 3 1.84 ± 0.08 5 2.93 ± 0.66 5
DDX41 1.11 ± 0.35 3 0.91 ± 0.21 3 1.66 ± 0.50 5 2.07 ± 0.65 5
DDX60 1.27 ± 0.24 11 0.82 ± 0.37 10 3.07 ± 1.24 12 4.74 ± 1.28 13
DHX9 1.04 ± 0.20 3 0.80 ± 0.07 3 1.01 ± 0.14 5 1.07 ± 0.09 5
DHX36 1.00 ± 0.02 3 0.79 ± 0.07 3 0.93 ± 0.11 5 1.08 ± 0.06 5
p202 ND 3 ND 3 ND 5 ND 5
p204 1.02 ± 0.14 3 0.47 ± 0.22 3 1.52 ± 0.41 5 3.82 ± 1.06 5
LRRFIP1 1.03 ± 0.17 3 0.84 ± 0.04 3 1.26 ± 0.40 5 0.97 ± 0.10 5
RIG-1 ND 3 ND 3 ND 5 ND 5
TLR9 1.07 ± 0.29 3 0.43 ± 0.18 3 1.35 ± 0.68 5 2.08 ± 0.46 5
Control, no tumor manipulation; EP, 50 μl saline injection followed by the delivery of eight 5 ms pulses with a voltage-to-distance ratio of 800 V/cm and fre-
quency 1 Hz with a caliper electrode; pDNA, injection of 50 μl 2 mg/ml gWiz Blank plasmid; EP+pDNA, injection of 50 μl 2 mg/ml gWiz Blank plasmid followed 
by the delivery of eight 5 ms pulses with a voltage-to-distance ratio of 800 V/cm and frequency 1 Hz with a caliper electrode.
aAIM2, absent in melanoma 2 (refs. 63–65); cGAS, cyclic guanosine monophosphate-adenosine monophosphate synthase40; DAI, DNA-dependent  activator 
of interferon regulatory factor32; DDX41, DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 (ref. 34); DDX60, DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (ref. 35); 
DHX9, DEAH (Asp-Glu-Ala-His) box helicase 9 (ref. 66); DHX36, DEAH (Asp-Glu-Ala-His) box helicase 36 (ref. 66); p202 (ref. 67); p204 (ref. 33); LRRFIP1; 
leucine-rich repeat flightless-interacting protein 1 (ref. 68); RIG-1, retinoic acid inducible gene upregulation of Type I interferon; TLR9, toll-like receptor 9 
(ref. 25). Mean ± SEM.  
ND, not detected.
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responses, although we demonstrate in vitro that pulse pro-
tocols with similar transfection efficiencies (Figure 3b) can 
correlate to different levels of DNA sensor mRNA upregula-
tion (Table 2). Using similar electrotransfer parameters, more 
than 50% of B16F1 cells were transfected in vitro, while only 
3% of tumor area was transfected in vivo.45 Another possibil-
ity is that this upregulation is masked by the inherent cellu-
lar heterogeneity of tumors. All nucleated cells can respond 
to type I interferons46,47 and both IFNβ mRNA and protein 
were significantly upregulated. Immune cells, fibroblasts, and 
endothelial cells residing in the tumor could exhibit differen-
tial DNA sensor upregulation, masking the DNA sensors acti-
vated in the tumor cells themselves.
In B16.F10 cells in vitro, IFNβ transcription, mRNA levels, 
and protein levels were significantly elevated after pDNA elec-
trotransfer but not after exposure to pDNA or electrotransfer 
individually (Figure 3). The mRNAs for DDX60, p204, and 
DAI were also significantly upregulated (Table 2). Other non-
viral transfections also activate these sensors; several groups 
used lipid transfection reagent in the original descriptions of 
these DNA sensors32,33,39,40,48 and these sensors are activated 
in other cell types by pDNA electrotransfer, such as C2C12 
mouse myoblasts (data not shown). Each of these DNA sen-
sors may induce the production of IFNβ when activated.32,33,35 
DDX60 and DAI are exclusively cytosolic; IFI16, the human 
ortholog of p204, is a nuclear sensor that moves to the cyto-
sol after activation.49 The interesting observation that p204 
mRNA is upregulated after pDNA electrotransfer may reflect 
the quantity of pDNA that reaches the nucleus. Since pDNA 
delivery to the nucleus is theoretically driven by endocy-
tosis,22,23 this sensor may be activated by any successful 
electrotransfer protocol to any cell type that expresses it. 
A significant increase in DDX60 protein confirmed the mRNA 
upregulation (Figure 2).
Figure 2 Levels of IFNβ and DDX-60 mRNA and protein after pDNA electrotransfer in B16.F10 mouse melanoma cells. (a) IFNβ 
mRNA levels as measured by real-time RT-PCR, n = 5–9. (b) IFNβ promotor activity as measured by luciferase expression, n = 4. (c) IFNβ 
protein levels as measured by ELISA, n = 3. (d) Fold cells positive for IFNβ as measured by flow cytometry normalized to the control, n = 6–8. 
(e) Median IFNβ fluorescent intensity as measured by flow cytometry normalized to the control, n = 6–8. (f) Fold cells positive for DDX60 
as measured by flow cytometry normalized to the control, n = 7. (g) Median DDX60 fluorescent intensity as measured by flow cytometry 
normalized to the control, n = 7. (h) Western blot of cell lysate demonstrating an increased expression of DDX60 9 hours after pDNA 
electrotransfer. Control, 40 μl of cells and 10 μl of saline; EP, 40 μl of cells and 10 μl of saline were electroporated by the delivery of eight 
5 ms pulses with a voltage-to-distance ratio of 600 V/cm with a plate electrode; pDNA, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid; 
EP+pDNA, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid were lectroporated by the delivery of eight 5 ms pulses with a voltage-to-
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Theoretically, the inhibition of endocytosis during electro-
transfer could reduce gene expression by preventing entry of 
pDNA into the cell or alternatively by driving pDNA delivery 
to the cytosol. MβCD pretreatment doubled the upregulation 
of IFNβ and DDX60 mRNA levels; however, DAI mRNA levels 
significantly decreased (P < 0.05. Tables 2 and 3). These 
discordant observations may support the possibility of differ-
ential distribution of DDX60 and DAI within the cytosol; after 
electrotransfer accompanied by reduced endocytosis, pDNA 
may be available to DDX60 but unavailable to DAI.
The cytosolic DNA sensors upregulated in our study are 
activated by a variety of nucleic acids and possess overlap-
ping downstream signaling pathways.28–31 DDX60 may bind 
both RNA and DNA35 and play a cell type- and/or ligand-
specific role.50,51 When stimulated by mammalian, bacte-
rial, viral, and synthetic dsDNA, DAI mediates the induction 
of proinflammatory molecules in a DNA dose-dependent 
manner.32 Similar to this study, DAI protein was upregu-
lated after challenge with herpes simplex virus type 1 in 
glial cells52 and transcription was increased in hepatocel-
lular carcinomas.53 After DNA electrotransfer to muscle, 
mRNA levels increased.54 In vivo pDNA electrotransfer of 
a plasmid encoding DAI acted as an adjuvant to a cancer 
vaccine delivery in mice.55
Even though human IFI16 and mouse p204 share only 
37% amino acid identity, both induce the production of IFNβ, 
but not IL-1β, in several cell types in response to DNA.33 
Interestingly, a fourfold increase in tumor IL-1β mRNA levels 
after pDNA electrotransfer (P < 0.05, data not shown) was 
not reflected in the B16.F10 cells in culture. This indicates 
that other cell types found in tumors, possibly immune cells, 
are also responding in vivo to pDNA electrotransfer. AIM2 
and TLR9 mRNAs are detected in melanoma tumors but not 
melanoma cells. This is not unexpected, since these proteins 
are probably expressed in other cell types present in tumors.
Combined, these results indicate that the B16.F10 mela-
noma cells themselves produce IFNβ after pDNA electro-
transfer, associated with the upregulation of multiple cytosolic 
DNA sensors. Programmed necrosis may contribute to the 
cell death observed in vitro, while both inflammation and 
programmed necrosis may contribute to the in vivo antitu-
mor effects in our study. DNA delivery by electroporation is a 
common in vitro laboratory technique, and activation of DNA 
sensors may be important to consider in specific research 
areas. Since research utilizing in vivo pDNA electrotransfer is 
often directed toward clinical applications, it is important and 
significant to completely understand the underlying mecha-
nisms involved.
The induction of inflammation may contribute to cancer-
targeted immune therapies. In a previous study of the antitu-
mor effects of vector electrotransfer, 70% of B16.F10 tumors 
completely regressed, and 70% of these tumor-free mice 
were resistant to challenge with B16.F10 cells,7 indicating the 
generation of an adaptive antitumor response. In a study of 
intratumor electrotransfer of a plasmid encoding IL-12 in the 
same tumor model, complete, long-term regression was pro-
duced in 89% of tumors.56 In this study, 100% of these mice 
were resistant to challenge with the same tumor cell line. 
A direct comparison is not possible since different plasmid 
backbones and differing tumor-directed pulse parameters 
were used in these studies; however, DNA sensor activation 
may contribute to the effectiveness of IL-12 as an antican-
cer therapy. Indeed, type I interferon production is required 
for the antitumor efficacy of a Semliki Forest virus encoding 
IL-12 (ref. 57).
The induction of inflammation may also aid in the induc-
tion of immune responses to vaccines58 and can be benefi-
cial in cancer gene therapies based on stimulation of immune 
responses. However, therapies requiring simple transgene 
expression may be inhibited when an immune response 
Table 2 Fold changes in mRNA levels of DNA sensors in B16.F10 tumor cells 4 hours after pDNA electrotransfer
Sensora Control N EP N EP1 N pDNA N EP+pDNA N EP1+pDNA N
AIM2 ND 3 ND 3 ND 3 ND 3 ND 3 ND 3
cGAS 1.18 ± 0.18 5 0.65 ± 0.12 3 2.35 ± 0.15 3 1.67 ± 0.27 3 2.05 ± 0.62 5 2.6 ± 0.24* 3
DAI 0.95 ± 0.25 5 1.15 ± 0.58 3 2.94 ± 0.27 3 2.01 ± 0.18 3 228.14 ± 72.47* 5 256.86 ± 17.90* 6
DDX41 0.84 ± 0.16 3 0.66 ± 0.26 3 1.91 ± 0.11 3 1.21 ± 0.06 3 0.72 ± 0.07 3 1.60 ± 0.01* 3
DDX60 1.04 ± 0.10 9 1.00 ± 0.52 8 2.27 ± 0.44 3 1.44 ± 0.56 7 6.92 ± 1.85* 8 42.16 ± 5.36* 6
DHX9 1.12 ± 0.23 7 0.54 ± 0.14 4 1.82 ± 0.06 3 0.35 ± 0.13 4 0.86 ± 0.43 6 1.67 ± 0.64 3
DHX36 1.15 ± 0.24 7 0.46 ± 0.11 5 2.51 ± 0.83 3 0.54 ± 0.10 4 0.94 ± 0.39 6 0.86 ± 0.06 3
p202 ND 3 ND 3 ND 3 ND 3 ND 3 ND 3
p204 1.22 ± 0.70 2 5.45 ± 3.04 2 1.82 ± 0.24 3 1.23 ± 0.75 3 21.79 ± 5.85* 4 44.51 ± 7.40* 5
LRRFIP1 0.85 ± 0.16 3 0.62 ± 0.20 3 1.35 ± 0.36 3 0.85 ± 0.06 5 0.74 ± 0.12 5 0.62 ± 0.23 3
RIG-1 ND 6 ND 5 ND 3 ND 6 ND 8 ND 3
TLR9 ND 5 ND 3 ND 3 ND 2 ND 7 ND 3
Control, 40 μl of cells and 10 μl of saline; EP, 40 μl of cells and 10 μl of saline were electroporated by the delivery of eight 5 ms pulses with a voltage-to-
distance ratio of 600 V/cm and frequency 1 Hz with a plate electrode; EP1, 40 μl of cells and 10 μl of saline were electroporated by the delivery of six 100 μs 
pulses with a voltage-to-distance ratio of 1,300 V/cm and frequency 4 Hz with a plate electrode; pDNA, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid; 
EP+pDNA, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid were electroporated by the delivery of eight 5 ms pulses with a voltage-to-distance ratio of 
600 V/cm with a plate electrode; EP1+pDNA, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid were electroporated by the delivery of six 100 μs pulses 
with a voltage-to-distance ratio of 1,300 V/cm and frequency 4 Hz with a plate electrode.
aAIM2, absent in melanoma 2; cGAS, cyclic guanosine monophosphate-adenosine monophosphate synthase; DAI, DNA-dependent activator of interferon 
regulatory factor; DDX41, DEAD (Asp-Glu-Ala-Asp) box polypeptide 41; DDX60, DEAD (Asp-Glu-Ala-Asp) box polypeptide 60; DHX9, DEAH (Asp-Glu-Ala-His) 
box helicase 9; DHX36, DEAH (Asp-Glu-Ala-His) box helicase 36; LRRFIP1; leucine-rich repeat flightless-interacting protein 1; RIG-1, retinoic acid inducible 
gene upregulation of Type I interferon; TLR9, toll-like receptor 9. Mean ± SEM. *Statistically significant difference compared to all groups (P < 0.05).
ND, not detected.
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Figure 3 Cell survival, transfection, cell death mechanism and morphology of B16.F10 cells after pDNA electrotransfer. Commercially 
prepared vector plasmid (gWiz Blank) was electrotransferred into B16.F10 melanoma cells. Control, 40 μl of cells and 10 μl of saline; pDNA 
1 mg/ml, 40 μl of cells and 10 μl of 1 mg/ml gWiz Blank plasmid; pDNA 2 mg/ml, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid; pDNA 
3.5 mg/ml, 40 μl of cells and 10 μl of 3.5 mg/ml gWiz Blank plasmid; EP, 40 μl of cells and 10 μl of saline were electroporated by the delivery of 
eight 5 ms pulses with a voltage-to-distance ratio of 600 V/cm with a plate electrode; EP+pDNA 1 mg/ml, 40 μl of cells and 10 μl of 1 mg/ml gWiz 
Blank plasmid were electroporated as described in EP group; EP+pDNA 2 mg/ml, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid were 
electroporated as described in EP group; EP+pDNA 3.5 mg/ml, 40 μl of cells and 10 μl of 3.5 mg/ml gWiz Blank plasmid were electroporated 
as described in EP group; EP1, 40 μl of cells and 10 μl of saline were electroporated by the delivery of six 100 μs pulses with a voltage-to-
distance ratio of 1300 V/cm and frequency 4 Hz with a plate electrode; EP1+pDNA 1 mg/ml, 40 μl of cells and 10 μl of 1 mg/ml gWiz Blank 
plasmid were electroporated as described in EP1 group; EP1+pDNA 2 mg/ml, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid were 
electroporated as described in EP1 group; EP1+ pDNA 3.5 mg/ml, 40 μl of cells and 10 μl of 3.5 mg/ml gWiz Blank plasmid were electroporated 
as described in EP1 group. For image B, 40 μl of cells and 10 μl of 2 mg/ml pEGFP-N1 plasmid were electroporated as previously described. 
(a) Cell survival was measured 72 hours after electrotransfer and was normalized to the control group. (b) Transfection efficiency of B16.F10 
cells after pEGFP-N1 electrotransfer after pDNA delivery with EP and EP1. *P < 0.05, statistically significant difference compared to all control 
groups and EP only. a.u., arbitrary units. (c) Cell death mechanism as quantified by flow cytometery and (d) cell morphology after pDNA 
electrotransfer. Blue arrows indicate necrotic cells displaying fragments of cytoplasm and only an outline of the nucleus. Black arrow indicates 

























































































































Table 3 Effect of the endocytosis inhibitor MβCD on fold changes in mRNA levels of IFNβ and DNA sensors in B16.F10 tumor cells 4 hours after DNA 
 electrotransfer
Control N EP N pDNA N EP+pDNA N
IFNβa 1.26 ± 0.36 8 0.99 ± 0.29 6 2.78 ± 1.06 6 140.93 ± 56.31* 10
DNA sensorsb
DAI 1.05 ± 0.19 4 1.39 ± 0.99 2 1.10 ± 0.02 2 9.39 ± 2.88* 6
DDX60 1.04 ± 0.12 8 1.39 ± 0.36 6 8.52 ± 2.97 5 15.56 ± 2.21* 10
TLR9 ND 4 ND 4 ND 4 ND 6
All cells were fisrt incubated in MβCD for 30 minutes then divided into four delivery groups. Control, 40 μl of cells and 10 μl of saline; EP, 40 μl of cells and 10 μl 
of saline were electroporated by the delivery of eight 5 ms pulses with a voltage-to-distance ratio of 600 V/cm and frequency 1 Hz with a plate electrode; pDNA, 
40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid; EP+pDNA, 40 μl of cells and 10 μl of 2 mg/ml gWiz Blank plasmid were electroporated by the delivery of 
eight 5 ms pulses with a voltage-to-distance ratio of 600 V/cm with a plate electrode.
aIFNβ, interferon β. bDAI, DNA-dependent activator of interferon regulatory factor; DDX60, DEAD (Asp-Glu-Ala-Asp) box polypeptide 60; TLR9, toll-like receptor 
9. Mean ± SE.
*Statistically significant difference compared to all groups (P < 0.05).
ND, not detected.
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is not desirable. To our knowledge, no pDNA electrotrans-
fer gene therapy has been inhibited by the innate immune 
response. However, this inhibition is a potential concern for 
certain gene therapies.59 DNA sensor upregulation and sub-
sequent activation of downstream signaling pathways should 
be fully understood in order to harness or control it for thera-
peutic applications.
Materials and methods
Plasmids. gWiz Blank, an empty vector, and gWiz Luc, which 
encodes the firefly luciferase gene driven by the CMV pro-
moter, were commercially prepared (Aldevron, Fargo, ND). 
The promoterless pGL3-Basic (Promega, Madison, WI) and 
pGL3-IFNβ-prom, which encodes firefly luciferase driven 
by the mouse IFNβ promoter, were kind gifts of Judith A. 
Smith.60 These plasmids and pEGFP-N1 (BD Biosciences 
Clontech, Palo Alto, CA), which encodes the enhanced green 
fluorescent protein gene driven by the CMV promoter, were 
prepared using Qiagen Maxi-Endo-Free Kits according to the 
manufacturer’s instructions. All plasmids were suspended at 
2 μg/μl in physiological saline unless otherwise noted.
Cells and tumors. All procedures were approved by the Vet-
erinary Administration of The Ministry of Agriculture and the 
Environment of the Republic of Slovenia (#34401–12/2009/6). 
B16F.10 mouse melanoma cells (ATCC CRL-6475, American 
Type Culture Collection, Manassas, VA) in the exponential growth 
phase were used in experiments in vitro and in vivo. For tumor 
induction, 1 × 106 B16.F10 melanoma cells in 50 μl phosphate-
buffered saline (PBS) were injected subcutaneously in the left 
flank of female 7–8-week-old C57Bl/6 mice (Envigo, Udine, Italy). 
Tumors were allowed to grow approximately 8 days to a mean 
tumor diameter of 4 mm before experiments were performed.
In vivo DNA electrotransfer. Mice were anesthetized using 
a mixture of 2.5% isoflurane and 97.5% O2. Tumors were 
injected with 50 μl of pDNA solution and eight square elec-
tric pulses with a voltage-to-distance ratio of 800 V/cm, a 
pulse duration of 5 ms, and a frequency 1 Hz were deliv-
ered through two parallel stainless steel electrodes using an 
Electro Cell B10 electric pulse generator (LEROY biotech, 
L’Union, France). Tumors were measured twice to three times 
weekly using a digital caliper. Tumor volume was calculated 
by the formula v = ab2π/6, where a is the longest diameter, 
and b is the next longest diameter perpendicular to a. Mice 
were humanely euthanized when the tumor volume reached 
1,000 mm3 or when the animal’s behavior indicated discom-
fort. Animals with tumors in regression were followed up to 
100 days and were considered to be in complete regres-
sion if no tumor regrowth was observed during this time. For 
postmortem tumor analysis, mice were humanely sacrificed, 
tumors removed, and snap frozen on dry ice.
Real-time reverse transcription PCR. RNA was extracted 
from tumors or cells 4 hours after electrotransfer using Trizol 
Reagent (Invitrogen, Carlsbad, CA) then purified using 
RNeasy columns (Qiagen, Valencia, CA). After extraction, 
250 ng of total RNA was transcribed into cDNA using the 
SuperScript VILO cDNA Synthesis Kit (Invitrogen, Thermo 
Fisher Scientific,Waltham, MA). according to manufactur-
er’s instructions and diluted 10-fold. Messenger RNA was 
quantified on a CFX96 Real Time PCR Detection System 
(Bio-Rad, Hercules, CA) or a Primus 25 advanced thermal 
cycler (Peqlab, Erlangen, Germany) using custom primers 
(Integrated DNA Technologies, Coralville, IA) in SYBR Green 
Master Mix (Applied Biosystems, Thermo Fisher Scientific 
Waltham, MA). See Supplementary Table S1 for primer 
sequences. Spleen RNA acted as a positive control. Relative 
quantification was performed by comparison to the house-
keeping genes β-actin and glyceraldehyde 3-phosphate 
dehydrogenase using the ΔΔCt method.61
Protein quantification by ELISA. Tumors were homogenized 
in PBS containing protease inhibitors and homogenates were 
centrifuged to remove cell debris. bicinchoninic acid (BCA) 
assays (Pierce Biotechnology, Rockford, IL) were performed 
and samples normalized to 1 mg/ml total protein. ELISAs 
were performed on the normalized homogenates per manu-
facturer’s instructions (PBL Assay Science, Piscataway, NJ).
Immunohistochemistry. Histological analysis was performed 
at three different time points, 6, 20, and 36 hours. Three mice 
from each experimental group were sacrificed in two indepen-
dent experiments. The tumors were excised at selected time 
point, fixed in immunohistochemistry (IHC) zinc fixative (BD 
Pharmingen, BD Biosciences, San Jose, CA) overnight, and 
embedded in paraffin. Consecutive 2-μm thick tumor sections 
were cut from each paraffin block. The first section of each 
tumor sample was stained with hematoxylin & eosin (H&E) 
and analyzed. Based on H&E staining, the appropriate time 
point for analysis of apoptosis was determined and following 
tumor sections were stained with rabbit monoclonal antibod-
ies against cleaved caspase-3 (Ca-3, Cell signaling Technol-
ogy, Danvers, MA, dilution 1:1,500). A peroxidase-conjugated 
streptavidin–biotin system (Rabbit-specific HRP/DAB detec-
tion IHC kit, ab64261, Abcam, Cambridge, England, UK) 
was used as a colorogenic reagent followed by hematoxylin 
counterstaining. The images of stained tumor sections were 
captured with a DP72 CCD camera connected to a BX-51 
microscope (Olympus, Hamburg, Germany). Whole tumor 
sections were captured at ×4 magnification for H&E staining 
and 5 images at ×60 magnification for Ca-3 staining. The per-
centage of tumor necrosis and the number of Ca-3-positive 
cells were determined by two independent observers.
In vitro DNA electrotransfer. Trypsinized B16.F10 mouse 
melanoma cells were suspended in electroporation buffer 
and pDNA added as described previously.62 Aliquots were 
transferred to cuvettes or pipetted between 2 mm gap steel 
electrodes. Two different pulse types were used, eight square 
wave electric pulses at an amplitude over distance ratio 
600 V/cm, a pulse duration of 5 ms, and a frequency 1 Hz 
(EP), and six square wave electric pulses at an amplitude 
over distance ratio 1,300 V/cm, a pulse duration of 100 μs, 
and a frequency of 4 Hz (EP1) electric pulses were gener-
ated by an in-house built electroporator (GT-01, Faculty of 
Electrical Engineering, University of Ljubljana, Slovenia) or 
with a T820 Electrosquare porator (BTX Molecular Delivery 
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Systems, Holliston, MA). Cells were immediately diluted in 
medium.
IFNβ transcription assay. Cells were transfected by DNA 
electrotransfer with pGL3-Basic, pGL3-IFNβ-prom, or gWiz 
Luc. After transfection, 2.5 × 105 cells in 100 μl medium per 
well were incubated 16 hours in white opaque 96-well plates. 
The medium was replaced with fresh medium containing 
250 μg/ml luciferin and luciferase expression was immedi-
ately quantified (Lumistar Omega, BMG Labtech, Cary, NC). 
The medium was again replaced with 100 μl medium contain-
ing PrestoBlue (Invitrogen, Thermo Fisher Scientific), incu-
bated for 2 hours, and viability quantified as determined by 
reducing ability (Gemini XPS, Molecular Devices, Sunnyvale, 
CA). Luciferase expression was normalized to viability.
Protein detection by flow cytometry. Immunofluorescence 
staining and subsequent flow cytometry analysis was per-
formed for protein level quantification. Cells were collected 
from 24-well ultra-low attachment plates 6 hours after elec-
trotransfer. Cells were fixed in 4% paraformaldehyde (Alfa 
Aesar, A Johnson Matthey Company, Ward Hill, MA) for 
15 minutes, permeabilized with 0.5% Tween 20 (TWEEN 
20, Sigma-Aldrich, Steinheim, DE) for 10 minutes and incu-
bated in 10% donkey serum (Sigma-Aldrich) for 30 minutes. 
Samples were incubated overnight at 4 °C with primary rabbit 
anti-mouse polyclonal antibodies (Anti-DDX60, ab139807, 
Abcam, dilution 1:100). Donkey anti-rabbit secondary 
 antibodies (Cy3 AffiniPure Donkey Anti-Rabbit IgG (H+L), 
711-165-152, Jackson ImmunoResearch Laboratories, West 
Grove, PA, dilution 1:150) were added and incubated for 
1 hour. Cells were washed with PBS between each step. Mea-
surements were performed with FACSCanto II flow cytom-
eter (BD Biosciences, San Jose, CA) with appropriate filters 
(excitation: 488 nm, emission: 530 nm). A histogram of cells 
gated to eliminate debris against their fluorescence intensity 
was recorded and the number of fluorescent cells and their 
median fluorescence intensity were determined (software: 
BD FACSDiva V6.1.2, BD Biosciences, San Jose, CA).
Protein detection by western blot. After performing assays at 
4, 6, 9, and 20 hours after pDNA electrotransfer, the highest 
expression of DDX60 was observed after 9 hours. Cells were 
collected and washed with ice-cold PBS from 24-well ultra-low 
attachment plates 9 hours after electrotransfer or trypsinyzed 
from 6 cm Petri-dish plate 20 hours after electrotransfer. Cell 
lysis was performed in radioimmuno precipitation assay lysis 
buffer supplemented with protease and phosphatase inhibi-
tors (Santa Cruz Biotechnology, Santa Cruz, CA) and incu-
bated on ice for 30 minutes with constant mixing. Whole-cell 
extracts were centrifuged and supernatants were collected. 
BCA assays (Pierce Biotechnology, Rockford, IL) were used 
for protein concentrations determination. A total of 25 μg of 
total proteins from each sample was separated on NuPAGE 
3–8% Tris-Acetate Midi-Gels for 35 minutes at 200 V using 
NuPAGE Tris Acetate Sample Buffer and dry transferred to 
a polyvinylidene fluoride membrane using iBlot Gel Transfer 
Stack (Invitrogen, Thermo Fisher Scientific, Waltham). The 
membranes were blocked with 5% low-fat dry milk (Pomurske 
mlekarne, Murska Sobota, Slovenia) in Tris-buffered saline 
(pH 7.4) containing 0.1% Tween-20 for 2 hours at room tem-
perature and then incubated with primary rabbit anti-mouse 
polyclonal antibodies, as listed in the section Protein detec-
tion by flow cytometry and β-actin (ab 75186, Abcam, dilu-
tion 1:1,000) as a loading control overnight at 4 °C. The next 
day washed membranes were incubated with horseradish 
peroxide- conjugated donkey anti-rabbit secondary antibody 
for 45 minutes at room temperature. Protein bands were 
detected with Image Quant LAS 4000 (GE Healthcare, Little 
Chalfont, UK) after 5 minutes incubation of the membrane in 
SuperSignal West Pico Chemiluminescent Substrate (Invitro-
gen, Thermo Fischer Scientific).
Cell survival assay. After electrotransfer of 1, 2, and 3.5 mg/
ml gWiz Blank plasmid, 1 × 103
 cells were cultured in 100 μl of 
medium in 96-well plates and incubated for 72 hours. Fresh 
medium containing Presto Blue (Invitrogen, Carlsbad, CA) 
was added to the cells and the fluorescence intensity was 
measured by microplate reader (Infinite 200, Tecan, Män-
nedorf, Switzerland) 30 minutes thereafter. Cell viability was 
normalized to control group.
Proliferation assay. After electrotransfer, cells were cultured 
in 6 cm Petri dishes for 16 hours to recover. Viable B16F10 
cells (2.5 × 102) were cultured in 100 μl of medium in 96-well 
plates for the proliferation assay. A Presto Blue assay was 
performed 2, 48, and 96 hours after viable cell culture 
according to manufacturer’s instructions. Cell proliferation in 
each experimental group was normalized to day 0 for that 
group. A second normalization to the untreated control group 
at day 4 was performed to determine percentage of reduced 
proliferation.
Determination of cell death mechanism. Cell death mecha-
nisms were determined 20 hours after pDNA electrotransfer 
using a FITC Annexin V Apoptosis Detection Kit with 7-AAD 
(7-amino-actinomycin D, BioLegend, San Diego, CA) accord-
ing to manufacturer’s instructions. A FACSCanto II flow 
cytometer (BD Biosciences, San Jose, CA), with a 488-nm 
laser (air-cooled, 20 mW solid state) was used for the excita-
tion and both 530 and 650-nm band-pass filter were used for 
detection of green and red fluorescence.
Cell morphology. For morphological observation of cells, 
cytospins were prepared. For each sample, a labeled slide, 
chamber and blotter were prepared and assembled. Six hours 
after pDNA electrotranfer, 80 μl of 1 × 103 B16.F10 cells 
were added to a slide chamber and spun at 1,000 rpm for 
4 minutes in a cytocentrifuge (Cytospin 2, Thermo Shandon, 
Runcorn, UK). The slides were air dried then stained with 
Giemsa’s Azure methylene blue solution (Merck, Germany) 
according to the manufacturer’s protocol. Cell images were 
captured with a DP72 CCD camera connected to a BX-51 
microscope.
Endocytosis inhibition. Cells were trypsinized and counted. 
4.5 × 106 B16F10 cells were incubated 30 minutes in 3.75 ml 
of medium containing 7.5 mmol/l methyl-β cyclodextrin 
(MβCD). Fifteen milliliters of electroporation buffer were 
added then cells were centrifuged and resuspended in 44 μl 
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of ice-cold electroporation buffer. 11 μl of 2 μg/μl gWiz Blank 
were added. 50 μl of the mixture was electroporated and total 
RNA was extracted for further analysis as described above.
Transfection efficiency. One day after pDNA electrotransfer, 
transfection efficiency was determined by fluorescent micros-
copy and quantified by flow cytometry. Three different obser-
vation fields of bright-field and fluorescent (exposure 400 ms) 
images of the cells were captured at ×100 objective magnifi-
cation with Olympus IX-70 (Hamburg, Germany) and appro-
priate filters (excitation: 460–490 nm, emission: 505 nm). The 
same samples were later trypsinized and resuspended in 
400 μl of phosphate-buffered saline for flow cytometry analy-
sis. Flow cytometry was performed as previously described.
Statistical analysis. For graphical representation and statisti-
cal analysis, SigmaPlot Software (Systat Software, Chicago, 
IL) was used. The data were first tested for normality of dis-
tribution with the Shapiro-Wilk test. The differences between 
the experimental groups were statistically evaluated by one-
way analysis of variance followed by a Holm-Sidak test for 
multiple comparison. A P value of less than 0.05 was consid-
ered to be statistically significant.
Supplementary material
Figure S1. The presence of inflammatory immune cells in 
melanoma tumor after pDNA electrotransfer.
Figure S2. Cell death mechanisms asdetermined by flow 
cytometry(FITC Annexin V Apoptosis Detection Kit with 
7-AAD, BioLegend, San Diego, CA, USA).
Table S1. Primers used in this study.
Acknowledgments The authors acknowledge the finan-
cial support from the state budget by the Slovenian Re-
search Agency (programs no. P3-0003, bilateral projects 
BI-US/13-14-007 and BI-US/15-16-019). Research reported 
in this publication was supported by the National Cancer In-
stitute of the National Institutes of Health under award num-
ber R01CA196796. The content is solely the responsibility of 
the authors and does not necessarily represent the official 
views of the National Institutes of Health. The research is a 
result of networking efforts within COST TD1104 Action. We 
would like to thank Mira Lavric, Andreja Brozic (Institute of 
Oncology Ljubljana, Ljubljana, Slovenia), Petra Hudler (Insti-
tute of Biochemistry, Medical Center for Molecular Biology, 
Faculty of Medicine, University of Ljubljana, Slovenia) and 
Andrej Coer (Faculty of Health Sciences, University of Pri-
morska, Slovenia) for all the valuable help they contributed 
to this paper. Plasmids pGL3-Basic (Promega, Madison, WI, 
USA) and pGL3-IFNβ-prom were kind gifts of Judith A. Smith, 
Department of Pediatrics, University of Wisconsin School of 
Medicine and Public Health, Madison, WI, USA.
The work was performed in Norfolk, Virginia, USA and Lju-
bljana, Slovenia.
 1. Cemazar, M, Golzio, M, Sersa, G, Rols, MP and Teissié, J (2006). Electrically-assisted 
nucleic acids delivery to tissues in vivo: where do we stand? Curr Pharm Des 12: 
3817–3825.
 2. Heller, LC and Heller, R (2006). In vivo electroporation for gene therapy. Hum Gene Ther 
17: 890–897.
 3. Favard, C, Dean, DS and Rols, MP (2007). Electrotransfer as a non viral method of gene 
delivery. Curr Gene Ther 7: 67–77.
 4. Heller, LC and Heller, R. Translation of electroporation mediated DNA delivery to the clinic. 
In: Markov M, Miklavcic D and Pakhomov A (eds.). Advanced Electroporation Techniques 
in Biology and Medicine. CRC Press: Boca Raton, FL; 2010. pp. 19-11-13.
 5. Heller, R and Heller, LC (2015). Gene electrotransfer clinical trials. Adv Genet 89: 235–262.
 6. Niu, G, Heller, R, Catlett-Falcone, R, Coppola, D, Jaroszeski, M, Dalton, W et al. (1999). 
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma 
B16 tumor in vivo. Cancer Res 59: 5059–5063.
 7. Heller, LC and Coppola, D (2002). Electrically mediated delivery of vector plasmid DNA 
elicits an antitumor effect. Gene Ther 9: 1321–1325.
 8. McCray, AN, Ugen, KE, Muthumani, K, Kim, JJ, Weiner, DB and Heller, R (2006). Complete 
regression of established subcutaneous B16 murine melanoma tumors after delivery of an 
HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther 14: 647–655.
 9. Ugen, KE, Kutzler, MA, Marrero, B, Westover, J, Coppola, D, Weiner, DB et al. (2006). 
Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-
expressing plasmid followed by in vivo electroporation. Cancer Gene Ther 13: 969–974.
 10. Heller, LC, Cruz, YL, Ferraro, B, Yang, H and Heller, R (2010). Plasmid injection and 
application of electric pulses alter endogenous mRNA and protein expression in B16.F10 
mouse melanomas. Cancer Gene Ther 17: 864–871.
 11. Heller, L, Todorovic, V and Cemazar, M (2013). Electrotransfer of single-stranded 
or double-stranded DNA induces complete regression of palpable B16.F10 mouse 
melanomas. Cancer Gene Ther 20: 695–700.
 12. Marrero, B, Shirley, S and Heller, R (2014). Delivery of interleukin-15 to B16 melanoma 
by electroporation leads to tumor regression and long-term survival. Technol Cancer Res 
Treat 13: 551–560.
 13. Slack, A, Bovenzi, V, Bigey, P, Ivanov, MA, Ramchandani, S, Bhattacharya, S et al. (2002). 
Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med 4: 381–389.
 14. Prud’homme, GJ, Glinka, Y, Khan, AS and Draghia-Akli, R (2006). Electroporation-
enhanced nonviral gene transfer for the prevention or treatment of immunological, 
endocrine and neoplastic diseases. Curr Gene Ther 6: 243–273.
 15. Grosel, A, Sersa, G, Kranjc, S and Cemazar, M (2006). Electrogene therapy with p53 of 
murine sarcomas alone or combined with electrochemotherapy using cisplatin. DNA Cell 
Biol 25: 674–683.
 16. Deharvengt, S, Rejiba, S, Wack, S, Aprahamian, M and Hajri, A (2007). Efficient 
electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine 
nucleoside phosphorylase suicide gene with fludarabine. Int J Oncol 30: 1397–1406.
 17. Radkevich-Brown, O, Piechocki, MP, Back, JB, Weise, AM, Pilon-Thomas, S and Wei, WZ 
(2010). Intratumoral DNA electroporation induces anti-tumor immunity and tumor 
regression. Cancer Immunol Immunother 59: 409–417.
 18. Wang, YS, Tsang, YW, Chi, CH, Chang, CC, Chu, RM and Chi, KH (2008). Synergistic 
anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus 
intra-tumor injection of dendritic cells. Cancer Lett 266: 275–285.
 19. Vidic, S, Markelc, B, Sersa, G, Coer, A, Kamensek, U, Tevz, G et al. (2010). MicroRNAs 
targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell 
growth in vitro and in vivo. Cancer Gene Ther 17: 409–419.
 20. Forde, PF, Sadadcharam, M, Hall, LJ, O’ Donovan, TR, de Kruijf, M, Byrne, WL et al.  
(2014). Enhancement of electroporation facilitated immunogene therapy via T-reg 
depletion. Cancer Gene Ther 21: 349–354.
 21. Forde, PF, Hall, LJ, de Kruijf, M, Bourke, MG, Doddy, T, Sadadcharam, M et al. (2015). 
Non-viral immune electrogene therapy induces potent antitumour responses and has a 
curative effect in murine colon adenocarcinoma and melanoma cancer models. Gene Ther 
22: 29–39.
 22. Wu, M and Yuan, F (2011). Membrane binding of plasmid DNA and endocytic pathways 
are involved in electrotransfection of mammalian cells. PLoS One 6: e20923.
 23. Rosazza, C, Phez, E, Escoffre, JM, Cézanne, L, Zumbusch, A and Rols, MP (2012). 
Cholesterol implications in plasmid DNA electrotransfer: Evidence for the involvement of 
endocytotic pathways. Int J Pharm 423: 134–143.
 24. Markelc, B, Skvarca, E, Dolinsek, T, Kloboves, VP, Coer, A, Sersa, G et al. (2015). Inhibitor 
of endocytosis impairs gene electrotransfer to mouse muscle in vivo. Bioelectrochemistry 
103: 111–119.
 25. Hemmi, H, Takeuchi, O, Kawai, T, Kaisho, T, Sato, S, Sanjo, H et al. (2000). A Toll-like 
receptor recognizes bacterial DNA. Nature 408: 740–745.
 26. Bertling, W, Hunger-Bertling, K and Cline, MJ (1987). Intranuclear uptake and persistence 
of biologically active DNA after electroporation of mammalian cells. J Biochem Biophys 
Methods 14: 223–232.
 27. Golzio, M, Teissie, J and Rols, MP (2002). Direct visualization at the single-cell level of 
electrically mediated gene delivery. Proc Natl Acad Sci USA 99: 1292–1297.
 28. Broz, P and Monack, DM (2013). Newly described pattern recognition receptors team up 
against intracellular pathogens. Nat Rev Immunol 13: 551–565.
 29. Desmet, CJ and Ishii, KJ (2012). Nucleic acid sensing at the interface between innate and 
adaptive immunity in vaccination. Nat Rev Immunol 12: 479–491.
 30. Hornung, V and Latz, E (2010). Intracellular DNA recognition. Nat Rev Immunol 10: 
123–130.
www.moleculartherapy.org/mtna
DNA Sensors Upregulated by DNA Electrotransfer
Znidar et al.
11
 31. Keating, SE, Baran, M and Bowie, AG (2011). Cytosolic DNA sensors regulating type I 
interferon induction. Trends Immunol 32: 574–581.
 32. Takaoka, A, Wang, Z, Choi, MK, Yanai, H, Negishi, H, Ban, T et al. (2007). DAI (DLM-1/
ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448: 
501–505.
 33. Unterholzner, L, Keating, SE, Baran, M, Horan, KA, Jensen, SB, Sharma, S et al. (2010). 
IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 11: 997–1004.
 34. Zhang, Z, Yuan, B, Bao, M, Lu, N, Kim, T and Liu, YJ (2011). The helicase DDX41 senses 
intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol 12: 
959–965.
 35. Miyashita, M, Oshiumi, H, Matsumoto, M and Seya, T (2011). DDX60, a DEXD/H box 
helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol 
Cell Biol 31: 3802–3819.
 36. Ablasser, A, Bauernfeind, F, Hartmann, G, Latz, E, Fitzgerald, KA and Hornung, V (2009). 
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase 
III-transcribed RNA intermediate. Nat Immunol 10: 1065–1072.
 37. Choi, MK, Wang, Z, Ban, T, Yanai, H, Lu, Y, Koshiba, R et al. (2009). A selective contribution 
of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic 
DNA. Proc Natl Acad Sci USA 106: 17870–17875.
 38. Ferguson, BJ, Mansur, DS, Peters, NE, Ren, H and Smith, GL (2012). DNA-PK is a DNA 
sensor for IRF-3-dependent innate immunity. Elife 1: e00047.
 39. Kondo, T, Kobayashi, J, Saitoh, T, Maruyama, K, Ishii, KJ, Barber, GN et al. (2013). DNA 
damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I 
interferon by regulating STING trafficking. Proc Natl Acad Sci USA 110: 2969–2974.
 40. Sun, L, Wu, J, Du, F, Chen, X and Chen, ZJ (2013). Cyclic GMP-AMP synthase is a 
cytosolic DNA sensor that activates the type I interferon pathway. Science 339: 786–791.
 41. Li, LH, Sen, A, Murphy, SP, Jahreis, GP, Fuji, H and Hui, SW (1999). Apoptosis induced by 
DNA uptake limits transfection efficiency. Exp Cell Res 253: 541–550.
 42. Upton, JW, Kaiser, WJ and Mocarski, ES (2012). DAI/ZBP1/DLM-1 complexes with RIP3 
to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus 
vIRA. Cell Host Microbe 11: 290–297.
 43. Aglipay, JA, Lee, SW, Okada, S, Fujiuchi, N, Ohtsuka, T, Kwak, JC et al. (2003). A member 
of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-
mediated apoptosis pathway. Oncogene 22: 8931–8938.
 44. Monroe, KM, Yang, Z, Johnson, JR, Geng, X, Doitsh, G, Krogan, NJ et al. (2014). IFI16 
DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. 
Science 343: 428–432.
 45. Cemazar, M, Sersa, G, Wilson, J, Tozer, GM, Hart, SL, Grosel, A et al. (2002). Effective 
gene transfer to solid tumors using different nonviral gene delivery techniques: 
electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 9: 399–406.
 46. Pichlmair, A and Reis e Sousa, C (2007). Innate recognition of viruses. Immunity 27: 
370–383.
 47. Randow, F, MacMicking, JD and James, LC (2013). Cellular self-defense: how cell-
autonomous immunity protects against pathogens. Science 340: 701–706.
 48. Zhang, X, Brann, TW, Zhou, M, Yang, J, Oguariri, RM, Lidie, KB et al. (2011). Cutting 
edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. 
J Immunol 186: 4541–4545.
 49. Kerur, N, Veettil, MV, Sharma-Walia, N, Bottero, V, Sadagopan, S, Otageri, P et al. (2011). 
IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to 
Kaposi Sarcoma-associated herpesvirus infection. Cell Host Microbe 9: 363–375.
 50. Oshiumi, H, Miyashita, M, Okamoto, M, Morioka, Y, Okabe, M, Matsumoto, M et al. (2015). 
DDX60 Is Involved in RIG-I-Dependent and Independent Antiviral Responses, and Its 
Function Is Attenuated by Virus-Induced EGFR Activation. Cell Rep 11: 1193–1207.
 51. Goubau, D, van der Veen, AG, Chakravarty, P, Lin, R, Rogers, N, Rehwinkel, J et al. (2015). 
Mouse superkiller-2-like helicase DDX60 is dispensable for type I IFN induction and 
immunity to multiple viruses. Eur J Immunol 45: 3386–3403.
 52. Furr, SR, Chauhan, VS, Moerdyk-Schauwecker, MJ and Marriott, I (2011). A role for  
DNA-dependent activator of interferon regulatory factor in the recognition of herpes 
simplex virus type 1 by glial cells. J Neuroinflammation 8: 99.
 53. Pham, TH, Kwon, KM, Kim, YE, Kim, KK and Ahn, JH (2013). DNA sensing-independent 
inhibition of herpes simplex virus 1 replication by DAI/ZBP1. J Virol 87: 3076–3086.
 54. Mann, CJ, Anguela, XM, Montané, J, Obach, M, Roca, C, Ruzo, A et al. (2012). Molecular 
signature of the immune and tissue response to non-coding plasmid DNA in skeletal 
muscle after electrotransfer. Gene Ther 19: 1177–1186.
 55. Lladser, A, Mougiakakos, D, Tufvesson, H, Ligtenberg, MA, Quest, AF, Kiessling, R et al. 
(2011). DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective 
antitumor CTL immunity. Mol Ther 19: 594–601.
 56. Lucas, ML and Heller, R (2003). IL-12 gene therapy using an electrically mediated nonviral 
approach reduces metastatic growth of melanoma. DNA Cell Biol 22: 755–763.
 57. Melero, I, Quetglas, JI, Reboredo, M, Dubrot, J, Rodriguez-Madoz, JR, Mancheño, U et al. 
 (2015). Strict requirement for vector-induced type I interferon in efficacious antitumor 
responses to virally encoded IL12. Cancer Res 75: 497–507.
 58. Babiuk, S, Baca-Estrada, ME, Foldvari, M, Middleton, DM, Rabussay, D, Widera, G 
et al. (2004). Increased gene expression and inflammatory cell infiltration caused by 
electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 
110: 1–10.
 59. Nayak, S and Herzog, RW (2010). Progress and prospects: immune responses to viral 
vectors. Gene Ther 17: 295–304.
 60. Zeng, L, Liu, YP, Sha, H, Chen, H, Qi, L and Smith, JA (2010). XBP-1 couples endoplasmic 
reticulum stress to augmented IFN-beta induction via a cis-acting enhancer in 
macrophages. J Immunol 185: 2324–2330.
 61. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using  
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
 62. Todorovic, V, Sersa, G, Mlakar, V, Glavac, D and Cemazar, M (2012). Assessment of 
the tumourigenic and metastatic properties of SK-MEL28 melanoma cells surviving 
electrochemotherapy with bleomycin. Radiol Oncol 46: 32–45.
 63. Bürckstümmer, T, Baumann, C, Blüml, S, Dixit, E, Dürnberger, G, Jahn, H et al. (2009). 
An  orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor 
for the inflammasome. Nat Immunol 10: 266–272.
 64. Fernandes-Alnemri, T, Yu, JW, Datta, P, Wu, J and Alnemri, ES (2009). AIM2 activates the 
inflammasome and cell death in response to cytoplasmic DNA. Nature 458: 509–513.
 65. Hornung, V, Ablasser, A, Charrel-Dennis, M, Bauernfeind, F, Horvath, G, Caffrey, DR 
et al. (2009). AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating 
inflammasome with ASC. Nature 458: 514–518.
 66. Kim, T, Pazhoor, S, Bao, M, Zhang, Z, Hanabuchi, S, Facchinetti, V et al. (2010). Aspartate-
glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial 
DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci USA 107: 15181–15186.
 67. Roberts, TL, Idris, A, Dunn, JA, Kelly, GM, Burnton, CM, Hodgson, S et al. (2009). HIN-200 
proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323: 
1057–1060.
 68. Yang, P, An, H, Liu, X, Wen, M, Zheng, Y, Rui, Y et al. (2010). The cytosolic nucleic acid 
sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent 
pathway. Nat Immunol 11: 487–494.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License. The images or other third party material in this article are 
included in the article’s Creative Commons license, unless indicated 
otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission 
from the license holder to reproduce the material. To view a copy of 
this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
© K Znidar et al. (2016)
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)
